Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genomics Precision Diagnostic > Hematology Precision Panel > Hereditary Hemorrhagic Telangiectasia Precision Panel

Hereditary Hemorrhagic Telangiectasia Precision Panel

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease (OWRD) is a rare autosomal dominant disease that affects blood vessels throughout the body, causing a vascular dysplasia that leads to an increase tendency of bleeding. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease (OWRD) is a rare autosomal dominant disease that affects blood vessels throughout the body, causing a vascular dysplasia that leads to an increase tendency of bleeding. The bleeding presents as arteriovenous malformations (AVMs) and telangiectasias in specific locations, a potential source of serios morbidity and mortality. It is characterized by nosebleeds, telangiectasias on the lips, hands and oral mucosa. Symptom on set may be delayed until the fourth decade of life or later, and prognosis is variable depending on the severity and location of the bleeding.   

  • The Igenomix Organic Hereditary Hemorrhagic Telangiectasia Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of recurrent bleeding ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

     

Indication

  • The Igenomix Hereditary Hemorrhagic Telangiectasia Precision Panel is indicated for those patients with a clinical suspicion or diagnosis of Hereditary Hemorrhagic Telangiectasia with or without the following manifestations: 
    • Spontaneous, recurrent nosebleeds 
    • Telangiectasia (dilated veins) 
    • Family history of HHT (first-degree relative) 
    • Hepatic or pulmonary bleeding 
    • Gastrointestinal bleeding 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
  • Early initiation of treatment with a multidisciplinary team in the form of medical therapy and surgical treatment to decrease the amount of hemorrhage and minimizing sequelae of arteriovenous malformations.  
  • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
  • Improvement of delineation of genotype-phenotype correlation.
  • Facilitate gene discovery, identify genetic modifiers to explain clinical variability and potentially define and increased spectrum of hereditary telangiectasia disorders.  

Genes & Diseases

Methodology

References

See scientific referrals

Shovlin, C. L., Simeoni, I., Downes, K., Frazer, Z. C., Megy, K., Bernabeu-Herrero, M. E., Shurr, A., Brimley, J., Patel, D., Kell, L., Stephens, J., Turbin, I. G., Aldred, M. A., Penkett, C. J., Ouwehand, W. H., Jovine, L., & Turro, E. (2020). Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. Blood, 136(17), 1907–1918. https://doi.org/10.1182/blood.2019004560 

Leng, H., Zhang, Q., & Shi, L. (2019). Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 33(7), 591–592. https://doi.org/10.13201/j.issn.1001-1781.2019.07.004 

McDonald, J., Wooderchak-Donahue, W., VanSant Webb, C., Whitehead, K., Stevenson, D. A., & Bayrak-Toydemir, P. (2015). Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Frontiers in genetics, 6, 1. https://doi.org/10.3389/fgene.2015.00001 

Major, T., Gindele, R., Szabó, Z., Jóni, N., Kis, Z., Bora, L., Bárdossy,P., Rácz, T., Karosi, T., & Bereczky, Z. (2019). A herediter haemorrhagiás teleangiectasia (Osler–Weber–Rendu-kór) genetikai diagnosztikája [Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)]. Orvosi hetilap, 160(18), 710–719. https://doi.org/10.1556/650.2019.31380 

Duffau, P., Lazarro, E., & Viallard, J. F. (2014). Maladie de Rendu-Osler [Hereditary hemorrhagic telangiectasia]. La Revue de medecine interne, 35(1), 21–27. https://doi.org/10.1016/j.revmed.2013.02.022 

McDonald, J., Bayrak-Toydemir, P., & Pyeritz, R. E. (2011). Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genetics in medicine : official journal of the American College of Medical Genetics, 13(7), 607–616. https://doi.org/10.1097/GIM.0b013e3182136d32 

descargar

Detail description

Download

Request Information

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic testing solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Complaints
Work with us
Terms and conditions

FOLLOW IGENOMIX

  + 96 390 53 10
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country/Region

[2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

Request Information


  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
  • Country/Region
  • +34 96 390 53 10
  • Clinic Portal
  • Request Information